

# NSCLC registry - an analysis of adjuvant chemotherapies

---

S. Wilhelm<sup>1</sup>, R. Göttel<sup>2</sup>, HW. Tessen<sup>3</sup>, Project team of Internal Oncology (PIO)

<sup>1</sup>Specialized oncology practice Güstrow, <sup>2</sup>rgb Onkologisches Management GmbH Sarstedt,

<sup>3</sup>Specialized oncology practice Goslar

## **Approach:**

Patients with a stage II or IIIA NSCLC in clinical trials benefit from cisplatin-based chemotherapy after a R0 resection of the primary tumor. Is this effect observed as well outside clinical trials (health care research)?

Therefore, data from the everyday experience of specialized oncology practices have been collected as part of a NSCLC registry since 2003. 88 practices from 15 federal states are involved.

## **Methods:**

We have analyzed data of the treatment of NSCLC (ICD-10 C34) within the national scientific history registry ONCOReg of the project team of internal oncology (PIO). The registry contains the documentation of a total of 29,306 patients from 377 practices, 2,543 of them NSCLC from 88 practices in 15 federal states.

## **Results:**

Evaluable patients: 2,191

Sex: 1,601 (73%) male; 590 (27%) female

Age at initial diagnosis: 67 (30-99) years median, 743 (29%) >70 years

Histology: 1,111 (51%) adenocarcinoma; 903 (41%) squamous-cell carcinoma, 177 other

Smokers: 918 (54%) yes; 784 (46%) no, 83 n.s.

Survival: OS as of initial diagnosis 18.5 months, as of metastasis 12.5 months

Primary surgery: 647 (29.5%)

319 (49%) patients thereof received an adjuvant chemotherapy.

UICC: 4 (1%) IA; 58 (18%) IB; 44 (14%) IIA; 96 (31%) IIB; 93 (29%) IIIA; 21 (7%) IIIB; 3 n.s.

Therapies: 243 (76%) vinorelbine/cisplatin; 24 (8%) vinorelbine/carboplatin; 15 (5%)

gemcitabine/carboplatin; 13 (4%) paclitaxel/carboplatin; 10 (3%) gemcitabine/cisplatin; 14 others

Duration of therapy: 84 days

Survival: DFS median 26.1 mths.; 5 years 29%; OS median 65.5 mths.; 5 years 54%

## **Conclusion**

A median overall survival of 65.5 months resp. a 5-year survival of 54% reflects the data from phase III trials for patients with an adjuvant chemotherapy.

The collection of data is to be continued.